A Phase 1 Study of IM-1021 in Participants With Advanced Cancer (NCT06823167) | Clinical Trial Compass
RecruitingPhase 1
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
United States, Denmark, France190 participantsStarted 2025-02-26
Plain-language summary
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Informed consent signed by the participant prior to conducting study-specific procedures
. ≥18 years of age
. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
. Histological or cytological diagnosis of:
. Participants must have adequate organ function.
. Participants must have a negative pregnancy test, be willing to practice highly effective methods of birth control, use condoms, and refrain from oocyte/sperm donation, as applicable, as detailed in the protocol.
. Participants must have relapsed or refractory disease and have received all approved and available therapeutic options.
. Participants must have measurable disease as per the relevant response assessment framework: Lugano Classification for lymphoma (except SLL), per iwCLL criteria for SLL , and per RECIST v.1.1 for solid tumors.
Exclusion criteria
. Previously treated with an ADC with a topoisomerase-1 inhibitor payload, except: Participants with triple negative breast cancer may have received up to one prior ADC with a topoisomerase-1 inhibitor payload.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is a Phase 1 trial focused on finding a safe dose of IM-1021 rather than proving it works, what does that mean for my personal risk compared to potential benefit at this stage?
2The trial is measuring treatment-emergent adverse events to establish safety — based on what you know about how IM-1021 works, what kinds of side effects should I be prepared to watch for and report?
3Given that this study covers both blood cancers and solid tumors, does my specific cancer type make me a more or less suitable candidate to discuss with the trial team?
4Before considering this Phase 1 study, are there standard treatments or other options I should try first, and how does joining an early-phase dose-finding trial fit into my overall treatment plan?
5If I were to discuss this trial with the study team, how would the required visits, monitoring schedule, and reporting of adverse events realistically fit into my daily life and existing care?'
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)
Timeframe: From first dose to 37 days following last dose of study treatment
2
Determine the recommended dose(s) and schedule(s) of IM-1021 for further development
Timeframe: From first dose to 37 days following last dose of study treatment
. Previously received a ROR1-targeted therapy (eg, ADC, cell therapy, or monoclonal antibody).
. History of an anaphylactic reaction to irinotecan or ≥ grade 3 GI toxicity to prior irinotecan.
. Life expectancy \< 12 weeks.
. Prior solid organ transplant.
. Participants with symptomatic ascites or pleural effusion. Participants who are clinically stable for at least 2 weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis or catheter) are eligible.
. For participants with known active central nervous system (CNS) disease
. For participants with solid tumors: Participant has a known active CNS primary tumor or metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to study entry, have no radiological evidence of new or enlarging brain metastases, and are off steroids or on a stable dose up to an equivalent of prednisone 10 mg/day for at least 15 days prior to first dose of study medication. Participants who have symptoms consistent with CNS metastasis must have a negative magnetic resonance imaging (MRI) or other clinically appropriate imaging study if the participant is not able to undergo contrast-enhanced MRI and approved by the Sponsor Medical Monitor during the screening period.